Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Chinese Journal of Pediatrics ; (12): 215-219, 2017.
Artigo em Chinês | WPRIM | ID: wpr-808255

RESUMO

Objective@#To analyze and summarize the clinical and molecular characteristics of the patients with multiple congenital anomalies- hypotonia-seizures syndrome 1 (MCAHS 1).@*Method@#Clinical data and test results were collected from a patient who was diagnosed with confirmed genetic basis of MCAHS 1 in Shanghai Children′s Medical Center since December 2015. The patient and his parents were examined by the next generation sequencing (NGS) technology using peripheral blood genomic DNA, and the relevant mutations identified by NGS were verified with Sanger sequencing. Related literature was searched from PubMed and Embase databases (from their establishment to January 2017) by using "PIGN gene" as a keyword, the retrieved articles were further reviewed for the clinical manifestations, results and prognosis of PIGN related variants.@*Result@#A nearly 4-month-old Chinese boy was presented with epilepsy, hypotonia, developmental delay, accompanied by nearly normal laboratory test results. The NGS analysis revealed a compound heterozygous variations in the PIGN gene, included a known splice site mutation (c.963G>A) which was inherited from his father, and a novel nonsense mutation (c.2773A>T, p.Lys925*) which was inherited from his mother. Nine associated articles were retrieved. Including our patient, a total of 22 cases were identified as the PIGN variants. The most common clinical manifestations were developmental delay, hypotonia, and epilepsy.Missense varients were most frequently found. Prognosis was poor. Eight cases died, while survived cased suffered from refractory epilepsy, profound mental retardation, muscle weakness, etc.@*Conclusion@#MCAHS1 is characterized by epilepsy, severe developmental delay, hypotonia, and may be accompanied by multiple malformations of other systems. Homozygous or compound heterozygous variants in PIGN gene are the cause of the disease.

2.
Biomédica (Bogotá) ; 35(2): 235-246, abr.-jun. 2015. ilus, graf, tab
Artigo em Espanhol | LILACS | ID: lil-754834

RESUMO

Introducción. La leishmaniasis es una enfermedad de gran impacto en la salud pública. La Organización Mundial de la Salud considera prioritaria la investigación orientada al desarrollo de medicamentos para su tratamiento. La exploración de la ruta del fosfatidil-inositol es interesante, ya que está implicada en la supervivencia del parásito mediante el control de la osmorregulación, el transporte a través de las membranas y la activación de diversos factores de transcripción. Objetivo. Proponer blancos para el desarrollo de medicamentos contra la leishmaniasis mediante el análisis bioinformático y el modelado matemático de esta ruta. Materiales y métodos. Se caracterizaron las proteínas pertenecientes a la ruta del fosfatidil-inositol en las bases de datos TriTrypDB y Pfam. Posteriormente, se hizo un análisis de similitud con las proteínas humanas mediante las herramientas InParanoid7 y OrthoMCL. Finalmente, se propuso un modelo booleano de la ruta, utilizando los programas PROMOT y CellNetAnalyzer. Resultados. Se reconstruyó y se describió la ruta de señalización del fosfatidil-inositol en Leishmania spp. El análisis de similitud con proteínas humanas determinó la viabilidad de las proteínas pertenecientes a la ruta del fosfatidil-inositol como potenciales blancos moleculares. Los modelos matemáticos permitieron integrar los elementos de la ruta y predecir un efecto inhibidor. Se propusieron los siguientes blancos para el desarrollo de medicamentos: inositol-3-fosfato-5-fosfatasa, fosfatidil-inositol-4-cinasa, fosfatidil-inositol-3,4,5-trisfosfato-3-fosfatasa, e inositol-polifosfato1P-fosfatasa. Conclusiones. La ruta de señalización del fosfatidil-inositol aparece como una alternativa sólida desde el punto de vista del modelo cualitativo y a partir de las proteínas encontradas. Se identificaron posibles blancos de medicamentos contra la leishmaniasis. Posteriormente, se buscarán medicamentos contra las proteínas detectadas y se hará la validación experimental.


Introduction: Leishmaniasis is a disease of high impact on public health. Research on drugs for its treatment is considered a priority by the World Health Organization. The phosphatidyl-inositol signaling pathway is interesting to explore because it is involved in the survival of the parasite, by controlling osmoregulation, transport through membranes, and activation of transcription factors. Objective: To propose drug targets against the disease through bioinformatic analysis and mathematical modeling of this signaling pathway. Materials and methods: The phosphatidyl-inositol pathway proteins were characterized through Pfam and TriTrypDB databases. Subsequently, a similarity analysis with human proteins was performed using the OrthoMCL and InParanoid7 tools. Finally, a boolean model of the pathway was proposed using PROMOT and CellNetAnalyzer softwares. Results: The phosphatidyl-inositol signaling pathway in Leishmania spp. was reconstructed and described. The similarity analysis determined the feasibility of the phosphatidyl-inositol pathway proteins as molecular targets. Mathematical models allowed integrating the elements of the path and predicted an inhibitor effect. The following were proposed as drug targets: inositol-3-phosphate-5-phosphatase, phosphatidylinositol-4-kinase, phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and Inositol-1P-polyphosphate phosphatase. Conclusion: The phosphatidyl-inositol signaling pathway is robust from the point of view of the qualitative model and the proteins found. Thus, potential drug targets against leishmaniasis were identified. Subsequently we will seek to detect drugs against this set of proteins and validate them experimentally .


Assuntos
Humanos , Biologia Computacional , Leishmania/efeitos dos fármacos , Modelos Teóricos , Fosfatidilinositóis/antagonistas & inibidores , Transdução de Sinais/efeitos dos fármacos , Leishmaniose/tratamento farmacológico , Terapia de Alvo Molecular , Fosfatidilinositóis/fisiologia
3.
Experimental & Molecular Medicine ; : 1-11, 2010.
Artigo em Inglês | WPRIM | ID: wpr-104284

RESUMO

Phospholipids are key components of cellular membrane and signaling. Among cellular phospholipids, phosphoinositides, phosphorylated derivatives of phosphatidylinositol are important as a participant in essential metabolic processes in animals. However, due to its low abundance in cells and tissues, it is difficult to identify the composition of phosphoinositides. Recent advances in mass spectrometric techniques, combined with established separation methods, have allowed the rapid and sensitive detection and quantification of a variety of lipid species including phosphoinositides. In this mini review, we briefly introduce progress in profiling of cellular phosphoinositides using mass spectrometry. We also summarize current progress of matrices development for the analysis of cellular phospholipids using matrix-assisted laser desorption/ionization mass spectrometry. The phosphoinositides profiling and phospholipids imaging will help us to understand how they function in a biological system and will provide a powerful tool for elucidating the mechanism of diseases such as diabetes, cancer and neurodegenerative diseases. The investigation of cellular phospholipids including phosphoinositides using electrospray ionization mass spectrometry and matrix-assisted laser desorption/ionization mass spectrometry will suggest new insights on human diseases, and on clinical application through drug development of lipid related diseases.


Assuntos
Animais , Humanos , Espectrometria de Massas/métodos , Fosfatidilinositóis/metabolismo , Fosfolipídeos/metabolismo , Espectrometria de Massas por Ionização por Electrospray , Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz
4.
Chinese Journal of Dermatology ; (12): 160-162, 2009.
Artigo em Chinês | WPRIM | ID: wpr-396196

RESUMO

Objective To investigate the relationship of the expression of phosphatidylinositol-3-kinase(PI3K)subunits,P85 and P110 to the pathogenesis of psoriasis.Methods Immunohistochemical staining for P85 and P110 was performed in the tissue specimens from patients with psoriasis(n=30),chronic dermatitis(n=20),seborrheic keratosis(n=20),squamous cell carcinoma(n=20),basal cell carcinoma(n=30)and normal human controls(n=10).The absorbance of immunostained tissue was quantified with image analysis system (Q550CW,Leica,Manheim,Germany).Statistical analysis was carried out by ANOVA,Results Among these groups,a significant difference was observed in the expression level of P110 in the epidermis(F=35.64,P<0.01),as well as in that of P85(F=59.98,P<0.01)and P110(F=323.23,P<0.01)in the lymphocytes infiltrating the lesion.Increased expression of P110 was found in the epidermis of psoriatic lesions compared with the lesions in the other disorders,whereas no significant difference was noticed among the other disorders.In the case of P85 and P110 expression in the lesion-infiltrating lymphocytes infiltrating the lesion,psoriasis and squamous cell carcinoma significantly differed from the other disorders,while no difference was observed between psoriasis and squamous cell carcinoma (P>0.05).Conclusions The high expression of P110 might be closely correlated to the hyperproliferation of keratinocytes;but filrther study is needed to clarify the relationship of increased expression of P85 and P110 to the activation and proliferation of lymphocytes in psoriatic lesions.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA